Rotavirus

Rotavirus is a highly infectious virus of the gut that typically affects babies and young children. The diarrhoeal disease can be fatal.

Rotavirus can cause severe gastroenteritis. Gastroenteritis is an infection of the gut (the stomach and intestines) and can cause diarrhoea, vomiting, tummy ache and fever. When these symptoms become severe, dangerous dehydration can occur.

Rotavirus can also lead to shock (when the body isn’t getting enough blood flow) and can be fatal for some children.

Rotavirus mainly affects children aged six months to two years.

The virus spreads by contact with the faeces of an infected person. This can happen when people don’t wash their hands properly after changing a nappy or going to the toilet.

The rotavirus vaccine is the best way to protect against rotavirus but in some developing countries, limited access to healthcare means families cannot vaccinate their children.

Who does it affect?

Rotavirus is the most common cause of severe diarrhoea in children worldwide causing about 215,000 deaths a year. More than 90 per cent are in low-income countries in Africa and Asia.
In Australia, before the vaccine was introduced, rotavirus hospitalised roughly 10,000 children aged under five each year.
Since the vaccine was introduced in Australia, child hospital admissions due to rotavirus have dropped by more than 70 per cent.
Almost all unvaccinated children will have experienced one or more rotavirus diarrhoeal episodes, regardless of their living conditions, by age five.

Our Rotavirus research

Although 114 countries have introduced rotavirus vaccines that we developed, and despite World Health Organization recommendations that all children should receive a rotavirus vaccine, more than 80 million children worldwide still do not have access. Research supported by the Bill & Melinda Gates Foundation helped us develop a rotavirus vaccine for newborns and trial it in Africa. This included finding a reduced dose was also producing a stronger immune response. The Indonesian vaccine manufacturer PT BioFarma is also completing another trial with results due in 2023 after which it is planned that the vaccine will available for large-scale use in Indonesia and globally.

Our Enteric Diseases group hosts the WHO Collaboration Centre for Child Health, the WHO Regional Reference Laboratory for the Western-Pacific Region and the Australian Rotavirus Surveillance Program. These programs monitor and test for rotavirus, and the programs contribute to rotavirus disease surveillance and characterisation of strains causing severe disease in people throughout Australia and across our region.

The group’s research includes understanding why some oral rotavirus vaccines do not provide good protection in infants in low-income settings.

The group has also responded to the challenges posed by the COVID-19 pandemic. Research has involved exploring the role of gut infection by SARS-CoV-2 in COVID-19 as well as establishing an environmental surveillance program for SARS-CoV-2 in wastewater in Indonesia in collaboration with the Universitas Gadja Mada, Yogyakarta.

Impacts of our research

The landmark discovery of the virus in 1973 led by Professor Ruth Bishop was a breakthrough in combatting one of the world’s biggest causes of infant deaths.
We contributed to global efforts to introduce rotavirus vaccines.
Oral rotavirus vaccination became part of Australia’s National Immunisation Program for infants in 2007, and in 2009 the World Health Organization recommended it for all national immunisation programs.
Four decades of research led to our development of a world first oral rotavirus vaccine for newborns, to take advantage of the time when mothers and their babies are likely to be in contact with healthcare providers in developing countries.
The potential for the newborn vaccine to save thousands of lives caught the attention of the Bill & Melinda Gates Foundation which has funded trials in Indonesia and Malawi providing evidence that the vaccine was safe and protective.

Our vision

No child should die from a preventable virus. Our aim is universal and ongoing rotavirus vaccination for all infants, preventing deaths and disease from severe diarrhoea. Rotavirus eradication is possible if effective and affordable vaccines are accessible to all.

Where to next?

The RV3BB vaccine manufactured by PT BioFarma Indonesia is completing clinical trials with plans to introduce into the routine immunization program for all babies in Indonesia from 2023.

Joomla Social ShareJoomla Social Comments and Sharing - share and comment on Joomla site to social media: Facebook, Twitter, LinkedI, Vkontakte, Odnoklassniki